1.4.2018 - JPMorgan Presentation v3B - no notes...Title Microsoft PowerPoint - 1.4.2018 - JPMorgan...
Transcript of 1.4.2018 - JPMorgan Presentation v3B - no notes...Title Microsoft PowerPoint - 1.4.2018 - JPMorgan...
4 January 2018 / CONFIDENTIAL
JPMorgan Presentation
Relentless. Passionate. Focused.™
1
4 January 2018 / CONFIDENTIAL 2
This presentation (together with any other statements or information that we may furnish to you) includes or may include certain statements, estimates and forward-looking projections with respect to Kiniksa or our anticipated future performance or events. Forward-looking statements frequently are used in discussing potential product applications, potential acquisitions or collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters.
Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. They reflect various assumptions of our management that may or may not prove to be correct. In addition, this presentation does not purport to be all-inclusive or contain all information that you may desire in considering an investment in Kiniksa. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Except as otherwise indicated, this presentation speaks as of the date indicated above. Kiniksaundertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
THIS PRESENTATION DOES NOT CONSTITUTE AN OFFER TO SELL TO, OR A SOLICITATION OF AN OFFER TO BUY FROM, ANYONE IN ANY STATE OR IN ANY OTHER JURISDICTION IN WHICH SUCH AN OFFER OR SOLICITATION IS NOT AUTHORIZED.
Forward Looking Statements
4 January 2018 / CONFIDENTIAL 3
KINIKSA
A company with a sequential pipeline, FIRMLY rooted in strong biologic
rationale, validated mechanisms, and designed to deliver near, mid and
long-term value
4 January 2018 / CONFIDENTIAL
Kiniksa Senior Team
4
Sanj K. PatelChairman & Chief Executive Officer
Steve MahoneyPresident & Chief Operating Officer
John PaoliniChief Medical Officer
Brendan ClassonHead of Research
Christine MaurerSVP Program Management
Carsten BoessChief Business Officer
Chris HeberligChief Financial Officer
4 January 2018 / CONFIDENTIAL 5
Global Vision
Focus on Rare/Specialty Diseases
Rapid Development
Meaningful Impact
Our StrategyAcquire, Discover & Rapidly Develop: Life-changing therapies for devastating diseases
4 January 2018 / CONFIDENTIAL
Rapid Progress
6
Program Status / Activity
KPL-716
JPMorgan Conference 2017
• Pre-IND Program
Program Status / Activity
KPL-914
To date
• Phase 3 start planned for 2018
KPL-301 • Phase 2 start planned for 2018
KPL-716 • Phase 2 start planned for 2018
KPL-045 • Currently in IND-enabling studies
KPL-404 • Currently in IND-enabling studies
Corporate • $80M Series A Financing Corporate • $40M Series B Financing
Research • Initiated discovery on noveln targets
4 January 2018 / CONFIDENTIAL
Kiniksa Pipeline
7
Program & Mechanism Preclin
KPL-914
Early Clinical
MidClinical Pivotal Indications / Status / Milestones RightsBLA MktIndication
OrphanInflammatory
Inflamm. Cardio
• *Commercially approved product
• Nominal revenue post-BLA transfer to Kiniksa• Transfers to Kiniksa
upon sBLA approval
• Starting lead-in study
• Anticipate P3 start in 2018• World Wide (ex.
Middle East)
Inflamm.Derm.
• Phase 1b study currently enrolling patients as proof-of-mechanism
• Planning P2b start in rare inflammatory in ‘18KPL-716 • World Wide
Autoimmune • Currently conducting IND-enabling studiesKPL-045 • World Wide
Autoimmune • Currently conducting IND-enabling studiesKPL-404 • World Wide
Autoimmune• Hundreds of patient years worth of data
• Kiniksa to conduct programs in smaller autoimmune diseases (P2 start in 2018)
KPL-301 • World Wide
4 January 2018 / CONFIDENTIAL
KPL-914
Kiniksa portfolio: Potential to treat broad spectrum of autoimmune & autoinflammatory diseases with high unmet need
8
Innate Modulator
Adaptive Modulator
Autoinflammatory(e.g., rare monogenetic fever diseases, IBD, etc)
Autoimmune(e.g., myasthenia gravis, ITP, pemphigus vulgaris)
KPL-301
KPL-716
KPL-045
KPL-404Indications
Immunity
KPL-914• Receptor cytokine trap and modulator of innate immunity
KPL-301• Monoclonal antibody inhibitor of a key growth factor for
monocytes and granulocytes (e.g., neutrophils, eosinophils and basophils)
KPL-716• Monoclonal antibody inhibitor two inflammatory cytokines
involved in Th2 response / cell mediated immunity, pruritus, fibrosis and barrier dysfunction
KPL-045• Monoclonal antibody inhibitor of a T-cell co-stimulatory
receptor inhibitor involved in activated T-memory function
KPL-404• Monoclonal antibody inhibitor of a central control node of T-
cell dependent, B-cell mediated humoral adaptive immunity
4 January 2018 / CONFIDENTIAL
KPL-301
Phase 2-ready
9
KPL-914 Phase 3-ready
KPL-716
Phase 1b
KPL-045
Pre-Clin
KPL-404
Pre-Clin
Receptor cytokine trap and modulator of innate immunity
• Approved and marketed biologic product
• Targeting rare inflammatory cardiovascular disease/high unmet need
• Strong scientific rationale/validated mechanism
• Clear rationale for differentiation across additional indications
• Starting lead-in study/preparing to initiate Phase 3 Pivotal in 2018
4 January 2018 / CONFIDENTIAL 10
KPL-914 KPL-716 KPL-045 KPL-404
Monoclonal antibody inhibiting signaling of key growth factor for monocytes and granulocytes
• Demonstrated safety and efficacy in large autoimmune disease thru P2b
• Focusing now on rare, debilitating diseases with less competition and higher unmet need
• Copious GMP drug supply to enable quick start of Phase 2 studies
• Pipeline-in-a-molecule potential
KPL-301 Phase 2-ready
4 January 2018 / CONFIDENTIAL
KPL-301
11
KPL-914 KPL-045 KPL-404
Monoclonal antibody inhibitor of two inflammatory cytokines involved in Th2 response / cell mediated immunity, pruritus, fibrosis and barrier dysfunction
• Highly differentiated mechanism (simultaneously interrupts 2 key pathways)
• Currently dosing Phase 1b study in patients
• Plan to start Phase 2 studies in 2018
• Pipeline-in-a-molecule potential
KPL-716 Phase 1b
4 January 2018 / CONFIDENTIAL
KPL-301
12
KPL-914 KPL-716 KPL-404
Monoclonal antibody inhibitor of a critical T-cell co-stimulatory receptor inhibitor involved in activated T-memory function
• Target implicated in autoimmune diseases by existing approved therapy
• Comprehensive non-clinical package
• Proof of mechanism in several validated pre-clinical models
• Pipeline-in-a-molecule potential
• Currently conducting IND-enabling studies
KPL-045 Pre-Clin
4 January 2018 / CONFIDENTIAL
KPL-301
13
KPL-914 KPL-716 KPL-045
Monoclonal antibody inhibitor of a central control node of T-cell dependent, B-cell mediated humoral adaptive immunity
• Established Proof of Concept in previous studies
• Potentially a best-in-class molecule
• Targeting a variety of rare and specialty autoimmune diseases
• Pipeline-in-a-molecule potential
• Currently conducting IND-enabling studies
KPL-404 Pre-Clin
4 January 2018 / CONFIDENTIAL
Kiniksa 2018 Plans Multiple programs in the clinic
Pivotal study in a rare, debilitating disease
Multiple discovery-stage programs
Additional molecules in IND-enabling studies
4 January 2018 / CONFIDENTIAL
Passion for Patients
15
Every Second Counts Every Second Counts!